UNITY BIOTECHNOLOGY, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • March 23rd, 2018 • Unity Biotechnology, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is effective as of [DATE] by and between Unity Biotechnology, Inc., a Delaware corporation (the “Company”), and [INDEMNITEE] (“Indemnitee”).
UNITY BIOTECHNOLOGY, INC.Stock Option Agreement • March 23rd, 2018 • Unity Biotechnology, Inc. • Pharmaceutical preparations • California
Unless otherwise defined herein, the terms defined in the 2013 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”).
UNITY BIOTECHNOLOGY, INC. EMPLOYMENT AGREEMENTEmployment Agreement • March 23rd, 2018 • Unity Biotechnology, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), entered into as of January 29, 2018 (the “Effective Date”), is made by and between Unity Biotechnology, Inc., a Delaware corporation (the “Company”) and Nathaniel David (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain offer letter by and between Executive and the Company dated as of April 20, 2009 (“Offer Letter”).
UNITY BIOTECHNOLOGY, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT March 15, 2018Investors’ Rights Agreement • March 23rd, 2018 • Unity Biotechnology, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is dated as of March 15, 2018, and is between Unity Biotechnology, Inc., a Delaware corporation (the “Company”), and the persons and entities listed on Exhibit A (each, an “Investor” and collectively, the “Investors”).
COMPOUND LIBRARY AND OPTION AGREEMENTCompound Library and Option Agreement • March 23rd, 2018 • Unity Biotechnology, Inc. • Pharmaceutical preparations • New York
This Compound Library and Option Agreement (the “Agreement”), dated as of February 2nd, 2016 (the “Signing Date”), is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (“Ascentage”), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (“Unity”), with a business address at 1700 Owens Street, Suite 535, San Francisco, California 95158. Ascentage and Unity are sometimes referred to herein as individually as a party and collectively as the parties.
SECOND AMENDMENT TO SPACE LICENSE AGREEMENTSpace License Agreement • March 23rd, 2018 • Unity Biotechnology, Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT TO SPACE LICENSE AGREEMENT (this “Amendment”) is entered into as of this 30th day of January, 2017 (the “Second Amendment Execution Date”), by and between BMR-BAYSHORE BOULEVARD LP, a Delaware limited partnership (“Owner”), and UNITY BIOTECHNOLOGY, INC., a Delaware corporation (“User”).
FIRST AMENDMENT TO SPACE LICENSE AGREEMENTSpace License Agreement • March 23rd, 2018 • Unity Biotechnology, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO SPACE LICENSE AGREEMENT (this “Amendment”) is entered into as of this 5th day of December, 2016 (the “First Amendment Execution Date”), by and between BMR-BAYSHORE BOULEVARD LP, a Delaware limited partnership (“Owner”), and UNITY BIOTECHNOLOGY, INC., a Delaware corporation (“User”).
APG1252 License AgreementApg1252 License Agreement • March 23rd, 2018 • Unity Biotechnology, Inc. • Pharmaceutical preparations • New York
This APG1252 License Agreement (the “Agreement”) effective as of the 2nd day of Feburary, 2016, (the “Signing Date”) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (“Ascentage”), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (“Unity”), with a business address at 1700 Owens Street, Suite 535, San Francisco, California 95158. Each of Ascentage and Unity shall be a “Party,” and both the “Parties.”
